News
AKYA
4.730
0.00%
0.000
Weekly Report: what happened at AKYA last week (0318-0322)?
Weekly Report · 3d ago
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the positive outlook.
Seeking Alpha · 03/20 08:33
Weekly Report: what happened at AKYA last week (0311-0315)?
Weekly Report · 03/18 09:01
Akoya Biosciences (AKYA) Gets a Buy from Piper Sandler
TipRanks · 03/12 10:36
Weekly Report: what happened at AKYA last week (0304-0308)?
Weekly Report · 03/11 09:01
Akoya Biosciences Is Maintained at Overweight by JP Morgan
Dow Jones · 03/06 16:16
Akoya Biosciences Price Target Cut to $10.00/Share From $12.00 by JP Morgan
Dow Jones · 03/06 16:16
JP Morgan Maintains Overweight on Akoya Biosciences, Lowers Price Target to $10
Benzinga · 03/06 16:06
Massaro Issues Buy Rating for Akoya Biosciences Amid Strong Financial Performance and Market Growth Potential
Mark Massaro, an analyst from BTIG, reiterated the Buy rating on Akoya Biosciences (AKYA) with a price target of $9.00. The company has achieved a record revenue in the fourth quarter and a year-over-year top-line growth of 29%.
TipRanks · 03/06 11:17
Akoya Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Akoya Biosciences Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 22 cents per share. Revenue rose 24.8% to $26.49 million from the same quarter last year. The mean expectation of analysts was for a loss of 27 cents.
Reuters · 03/05 23:35
Akoya Biosciences Is Maintained at Buy by UBS
Dow Jones · 03/05 14:54
Akoya Biosciences Price Target Raised to $7.50/Share From $7.00 by UBS
Dow Jones · 03/05 14:54
UBS Maintains Buy on Akoya Biosciences, Raises Price Target to $7.5
Benzinga · 03/05 14:44
Akoya Biosciences Price Target Maintained With a $10.00/Share by Canaccord Genuity
Dow Jones · 03/05 14:08
Canaccord Genuity Reiterates Buy on Akoya Biosciences, Maintains $10 Price Target
Benzinga · 03/05 13:58
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
AKYA Stock Earnings: Akoya Biosciences Beats EPS, Beats Revenue for Q4 2023
Akoya Biosciences reported earnings per share of -22 cents. The company reported revenue of $26.49 million. This was 2.31% better than the analyst estimate for the company to report revenue of -20 million. The stock was down 2.7% after the market closed.
Investorplace · 03/05 01:51
Akoya Biosciences Sees FY24 Revenue $114M-$118M Vs $117.38M Est.
Benzinga · 03/04 21:40
Recap: Akoya Biosciences Q4 Earnings
Akoya Biosciences reported its Q4 earnings of $-0.22 on March 4. The company's revenue was up $5.27 million from the same period last year. Akoya B biosciences beat estimates by 19.0%. The company is expected to announce its earnings Monday.
Benzinga · 03/04 21:15
Akoya Biosciences Q4 2023 GAAP EPS $(0.22) Beats $(0.28) Estimate, Sales $26.49M Beat $25.89M Estimate
Akoya Biosciences reported quarterly losses of $0.22 per share. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $25.89 million. Akoya also reported a 24.83 percent increase in sales over the same period last year.
Benzinga · 03/04 21:15
More
Webull provides a variety of real-time AKYA stock news. You can receive the latest news about Akoya Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AKYA
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).